SCHEMBL10000179

SCHEMBL10000179

CC1=CN=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10296430 0.71
SCHEMBL19386534 0.67
SCHEMBL19337462 0.67
SCHEMBL20366907 0.64
SCHEMBL20349157 0.63
SCHEMBL13258567 0.63 NISCH (0.36)
SCHEMBL10296434 0.59
SCHEMBL8758 0.58
SCHEMBL895220 0.58
SCHEMBL21584353 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037414-B2 Processes for preparing pharmaceutically relevant peptides STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 US disclosed
WO-2024080792-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARM. CO., LTD. (KR) 2024-04-18 WO disclosed
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders Technische Universität Darmstadt (DE) 2023-12-05 US disclosed
US-20230340055-A1 GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF Ascendis Pharma Oncology Division A/S (DK) 2023-10-26 US disclosed
US-20230340055-A1 GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF Ascendis Pharma Oncology Division A/S (DK) 2023-10-26 US disclosed
US-20230302091-A1 Combination Therapy with Controlled-Release CNP Agonists ASCENDIS PHARMA GROWTH DISORDERS AS (DK) 2023-09-28 US disclosed
US-20230302091-A1 Combination Therapy with Controlled-Release CNP Agonists ASCENDIS PHARMA GROWTH DISORDERS AS (DK) 2023-09-28 US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-3611165-B1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) 2023-08-16 EP disclosed
US-20230212185-A1 HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS Technische Universität Darmstadt (DE) 2023-07-06 US disclosed
US-7323570-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2008-01-29 US disclosed
US-20080021055-A1 Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists AVENTIS PHARMA S.A. 2008-01-24 US disclosed
US-7300933-B2 Diazabicyclic biaryl derivatives NEUROSEARCH A/S (DK) 2007-11-27 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
US-20070191395-A1 Heterocyclic compounds having antifungal activity DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
US-20070191312-A1 NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS MUSICKI BRANISLAV 2007-08-16 US disclosed
US-7223753-B2 Diazabicyclic biaryl derivatives NEUROSEARCH A/S (DK) 2007-05-29 US disclosed
US-20070054933-A1 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators MERCK & CO., INC (US) 2007-03-08 US disclosed
US-20070049495-A1 Ethylene derivatives and pesticides containing said derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-03-01 US disclosed
US-20070032466-A1 Drug containing chymase inhibitor as the active ingredient TEIJIN PHARMA LIMITED (JP) 2007-02-08 US disclosed